Inspiremd, INC

InspireMD, Inc. announced the elimination of its Chief Commercial Officer position, with Shane Gleason's last day of employment set for July 31, 2026.

InspireMD received a Nasdaq delisting warning due to failing to meet the minimum bid price requirement, with 180 days to regain compliance.

InspireMD, Inc. announced the resignation of board member Raymond W. Cohen, effective July 1, 2026, due to personal considerations.

InspireMD reports 100% acute device success and no major adverse events in its CGUARDIANS II clinical trial for the CGuard Prime 80 cm implant in TCAR procedures, awaiting FDA review.

InspireMD's 2026 annual meeting saw stockholders approve a significant increase in authorized common stock, alongside director re-elections and auditor ratification.

InspireMD announced that Board Chair Paul Stuka will not seek reelection at the 2027 Annual Meeting, initiating a formal succession planning process.

InspireMD, Inc. reported a 122% revenue increase for Q1 2026 driven by CGuard Prime's US launch, but faces substantial doubt about its ability to continue as a going concern.

InspireMD reports significant revenue growth in Q3 2025 driven by the US commercial launch of its CGuard Prime carotid stent system, despite increased net losses and ongoing liquidity concerns.

InspireMD reported a significant increase in net loss for Q2 2025, driven by higher operating expenses, despite securing key regulatory approvals and raising $40.1 million in new capital.

InspireMD's Q1 2025 results show stable revenue but increased net losses due to higher operating expenses related to U.S. expansion and R&D investments.

InspireMD saw a revenue increase of 16.3% in Q3 2024 compared to Q3 2023, but also experienced a significant rise in net losses.

InspireMD's Q2 2024 results show increased revenue but a larger net loss due to higher operating expenses, alongside positive one-year follow-up data from their C-GUARDIANS trial.

InspireMD's C-GUARDIANS trial demonstrates positive one-year follow-up results, supporting a PMA submission for potential FDA approval of the CGuard Prime carotid stent system in the first half of 2025.

InspireMD's annual 10-K filing outlines its capital structure, stock details, and regulatory compliance, highlighting its focus on the CGuard stent system and future growth.

Chief Commercial Officer Shane Gleason sold shares of InspireMD common stock to satisfy tax withholding obligations related to restricted stock vesting.

Director Paul Stuka acquired 15,000 shares of InspireMD, Inc. common stock through open market purchases.

CEO and President Marvin Slosman acquired 21,000 shares of InspireMD, Inc. common stock at $1.20 per share.

InspireMD, Inc. Director Paul Stuka has filed an amended Form 4 detailing adjustments to his beneficial ownership of company stock, clarifying previous reporting errors.

Director Paul Stuka purchased 75,626 shares of InspireMD common stock across two transactions in May 2026.

Director Scott R. Ward acquired 89,250 shares of InspireMD, Inc. common stock through open market purchases.

InspireMD, Inc. has scheduled its 2026 Annual Meeting for June 3, 2026, to elect directors and seek approval to increase authorized common stock to 250 million shares.

InspireMD, Inc. files a definitive proxy statement with the Securities and Exchange Commission.

InspireMD announces its 2025 Annual Meeting of Stockholders to be held on June 3, 2025, featuring proposals for director elections and auditor ratification.

InspireMD, Inc. files a definitive proxy statement with the Securities and Exchange Commission.

InspireMD, Inc. will hold its annual stockholder meeting on June 10, 2024, to vote on director elections, executive compensation, auditor ratification, and other business matters.

CEO Marvin Slosman files a Schedule 13D reporting beneficial ownership of 5.18% of InspireMD, Inc. common stock.

Craig Shore, a citizen of Israel and the United States, has filed an amendment to his Schedule 13D, reporting beneficial ownership of 3.5% of InspireMD, Inc.'s common stock.

InspireMD's CFO, Michael A. Lawless, reports beneficial ownership of 8.6% of common stock, including new equity grants and voting control over employee shares.

Nantahala Capital Management, LLC and its principals have reported a 9.99% beneficial ownership stake in InspireMD, Inc. as of March 31, 2026.

Velan Capital Master Fund LP and affiliated entities have reported beneficial ownership of 4.99% of InspireMD, Inc. common stock as of March 31, 2026.

Rosalind Advisors and affiliated funds reported a 9.2% beneficial ownership in InspireMD, Inc., primarily through common stock and warrants, with exercise limitations due to blocker provisions.

Aberdeen Group plc and abrdn Inc. have reported a shared beneficial ownership of 7.49% of InspireMD, Inc.'s common stock.

OrbiMed Advisors LLC has filed an Amendment No. 3 to Schedule 13G, reporting a 4.1% beneficial ownership stake in InspireMD, Inc.'s common stock.

Nantahala Capital Management, LLC and its managing members have disclosed a 9.99% beneficial ownership stake in InspireMD, Inc., including shares acquirable via warrants.